Item Type | Name |
Concept
|
Breast Neoplasms
|
Concept
|
Breast Neoplasms, Male
|
Concept
|
Inflammatory Breast Neoplasms
|
Academic Article
|
Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099.
|
Academic Article
|
Circulating tumor cells as prognostic marker in metastatic breast cancer.
|
Academic Article
|
Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience.
|
Academic Article
|
Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
|
Academic Article
|
Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer.
|
Academic Article
|
Dyadic coping in metastatic breast cancer.
|
Academic Article
|
Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer.
|
Academic Article
|
Proceedings of the First International Inflammatory Breast Cancer Conference.
|
Academic Article
|
Suberoylanilide hydroxamic acid blocks self-renewal and homotypic aggregation of inflammatory breast cancer spheroids.
|
Academic Article
|
Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4.
|
Academic Article
|
Novel targeted therapies in inflammatory breast cancer.
|
Academic Article
|
Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.
|
Academic Article
|
Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.
|
Academic Article
|
18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer.
|
Academic Article
|
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.
|
Academic Article
|
Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells.
|
Academic Article
|
Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells.
|
Academic Article
|
Molecular mechanisms of metastasis in breast cancer--clinical applications.
|
Academic Article
|
Inflammatory breast cancer: the disease, the biology, the treatment.
|
Academic Article
|
Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer.
|
Academic Article
|
A global approach to inflammatory breast cancer.
|
Academic Article
|
Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series.
|
Academic Article
|
Inflammatory breast cancer.
|
Academic Article
|
Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44?CD24lo cancer stem cell phenotype.
|
Academic Article
|
Mesenchymal stem cells expressing GD2 and CD271 correlate with breast cancer-initiating cells in bone marrow.
|
Academic Article
|
Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy.
|
Academic Article
|
Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study.
|
Academic Article
|
Circulating tumor cells in breast cancer: a tool whose time has come of age.
|
Academic Article
|
Inflammatory breast cancer: what progress have we made?
|
Academic Article
|
Serum HER2 levels determined by two methods in patients with metastatic breast cancer.
|
Academic Article
|
Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer.
|
Academic Article
|
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.
|
Academic Article
|
Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients.
|
Academic Article
|
Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
|
Academic Article
|
Circulating tumor cells and PET.
|
Academic Article
|
MRI features of inflammatory breast cancer.
|
Academic Article
|
A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer.
|
Academic Article
|
Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer.
|
Academic Article
|
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.
|
Academic Article
|
CTCs in metastatic breast cancer.
|
Academic Article
|
Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells.
|
Academic Article
|
Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer.
|
Academic Article
|
The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy.
|
Academic Article
|
Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone.
|
Academic Article
|
Brain metastasis in breast cancer: last barrier to the cure?
|
Academic Article
|
Epithelial-Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer.
|
Academic Article
|
Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation.
|
Academic Article
|
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.
|
Academic Article
|
Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients.
|
Academic Article
|
Circulating tumor cells (CTCs) in breast cancer: a diagnostic tool for prognosis and molecular analysis.
|
Academic Article
|
The role of circulating tumor cells in breast cancer diagnosis and prediction of therapy response.
|
Academic Article
|
Genomic and expression analysis of microdissected inflammatory breast cancer.
|
Academic Article
|
Genome Wide Proteomics of ERBB2 and EGFR and Other Oncogenic Pathways in Inflammatory Breast Cancer.
|
Academic Article
|
Inflammatory breast cancer (IBC): clues for targeted therapies.
|
Academic Article
|
Circulating tumor DNA to monitor metastatic breast cancer.
|
Academic Article
|
Automated electrorotation to reveal dielectric variations related to HER-2/neu overexpression in MCF-7 sublines.
|
Academic Article
|
Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer.
|
Academic Article
|
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
|
Academic Article
|
Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma.
|
Academic Article
|
Molecular prognostic factors for breast cancer metastasis and survival.
|
Academic Article
|
High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer.
|
Academic Article
|
Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy.
|
Academic Article
|
Update on the management of inflammatory breast cancer.
|
Academic Article
|
Nipple aspirate fluid cytology in breast carcinoma.
|
Academic Article
|
Chest wall recurrence after mastectomy does not always portend a dismal outcome.
|
Academic Article
|
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.
|
Academic Article
|
A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer.
|
Academic Article
|
A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma.
|
Academic Article
|
Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.
|
Academic Article
|
Inflammatory breast carcinoma: the sphinx of breast cancer research.
|
Academic Article
|
Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience.
|
Academic Article
|
Expression of c-kit proto-oncogene product in breast tissue.
|
Academic Article
|
Breast cancer highlights: key findings from the San Antonio Breast Cancer Symposium: a U.S. perspective.
|
Academic Article
|
Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy.
|
Academic Article
|
Circulating tumor cells, disease progression, and survival in metastatic breast cancer.
|
Academic Article
|
Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma.
|
Academic Article
|
Feasibility and utility of using chromosomal aneusomy to further define the cytologic categories in nipple aspirate fluid specimens: a preliminary study.
|
Academic Article
|
Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment.
|
Academic Article
|
p53 expression as a prognostic marker in inflammatory breast cancer.
|
Academic Article
|
The "microscopic" revolution in breast carcinoma.
|
Academic Article
|
Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes.
|
Academic Article
|
Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma.
|
Academic Article
|
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.
|
Academic Article
|
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
|
Academic Article
|
CD44 expression is associated with increased survival in node-negative invasive breast carcinoma.
|
Academic Article
|
Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
|
Academic Article
|
Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer.
|
Academic Article
|
Inflammatory breast cancer and high-dose chemotherapy: back to the past.
|
Academic Article
|
Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence.
|
Academic Article
|
Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy.
|
Academic Article
|
Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors.
|
Academic Article
|
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
|
Academic Article
|
Breast cancer molecular subtypes respond differently to preoperative chemotherapy.
|
Academic Article
|
Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy.
|
Academic Article
|
Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer.
|
Academic Article
|
The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
|
Academic Article
|
Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy.
|
Academic Article
|
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
|
Academic Article
|
The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer.
|
Academic Article
|
Systemic treatments for inflammatory breast cancer.
|
Academic Article
|
Circulating tumor cells, disease progression, and survival in metastatic breast cancer.
|
Academic Article
|
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival.
|
Academic Article
|
A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach.
|
Academic Article
|
Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer.
|
Academic Article
|
Circulating tumor cells in breast cancer: Advanced tools for "tailored" therapy?
|
Academic Article
|
Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer.
|
Academic Article
|
Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
|
Academic Article
|
Biologic markers in axillary node-negative breast cancer: differential expression in invasive ductal carcinoma versus invasive lobular carcinoma.
|
Academic Article
|
Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system.
|
Academic Article
|
Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden.
|
Academic Article
|
A gene signature in breast cancer.
|
Academic Article
|
New generation of molecular prognostic and predictive tests for breast cancer.
|
Academic Article
|
What progress have we made in managing inflammatory breast cancer?
|
Academic Article
|
Integrating circulating tumor cell assays into the management of breast cancer.
|
Academic Article
|
Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings.
|
Academic Article
|
Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease.
|
Academic Article
|
Trends for inflammatory breast cancer: is survival improving?
|
Academic Article
|
Prognostic value of initial clinical disease stage after achieving pathological complete response.
|
Academic Article
|
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
|
Academic Article
|
Prognostic significance of HER-2 status in women with inflammatory breast cancer.
|
Academic Article
|
Inflammatory breast cancer: defining a new entity.
|
Academic Article
|
Defining the clinical diagnosis of inflammatory breast cancer.
|
Academic Article
|
The medical treatment of inflammatory breast cancer.
|
Academic Article
|
Imaging and dosimetry of 99mTc EC annexin V: preliminary clinical study targeting apoptosis in breast tumors.
|
Academic Article
|
HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer.
|
Academic Article
|
Prognostic value of body mass index in locally advanced breast cancer.
|
Academic Article
|
Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT.
|
Academic Article
|
Locoregional treatment outcomes after multimodality management of inflammatory breast cancer.
|
Academic Article
|
Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy.
|
Academic Article
|
Breast cancer in the asian Indian population of the United States: a call for screening and education.
|
Academic Article
|
Circulating tumor cells in breast cancer: fiction or reality?
|
Academic Article
|
Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow.
|
Academic Article
|
Nanotechnology for breast cancer therapy.
|
Academic Article
|
Risk of ipsilateral lung cancer after postmastectomy radiotherapy and smoking: does the possible triumph over the actual?
|
Academic Article
|
Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?
|
Academic Article
|
Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.
|
Academic Article
|
Chronic thyroiditis in patients with advanced breast carcinoma: metabolic and morphologic changes on PET-CT.
|
Academic Article
|
Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data.
|
Academic Article
|
Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells.
|
Academic Article
|
Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma.
|
Academic Article
|
Primary peritoneal serous carcinoma presenting as inflammatory breast cancer.
|
Academic Article
|
Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
|
Academic Article
|
Molecular targets for treatment of inflammatory breast cancer.
|
Academic Article
|
Breast cancer metastasis: challenges and opportunities.
|
Academic Article
|
A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer.
|
Academic Article
|
Re: Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells.
|
Academic Article
|
Inflammatory breast cancer.
|
Academic Article
|
Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer.
|
Academic Article
|
GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer.
|
Academic Article
|
The biological information obtainable from circulating tumor cells.
|
Academic Article
|
CXCR4 expression in early breast cancer and risk of distant recurrence.
|
Academic Article
|
Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets.
|
Academic Article
|
Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.
|
Academic Article
|
A Comparison of Epidemiology, Biology, and Prognosis of Inflammatory Breast Cancer in Japanese and US Populations.
|
Academic Article
|
Presence of anaplastic lymphoma kinase in inflammatory breast cancer.
|
Academic Article
|
EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells.
|
Academic Article
|
Antitumor Response of an ERBB2 Amplified Inflammatory Breast Carcinoma With EGFR Mutation to the EGFR-TKI Erlotinib.
|
Academic Article
|
Emergence of Constitutively Active Estrogen Receptor-a Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer.
|
Academic Article
|
The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis.
|
Academic Article
|
Aldehyde dehydrogenase1 immunohistochemical staining in primary breast cancer cells independently predicted overall survival but did not correlate with the presence of circulating or disseminated tumors cells.
|
Academic Article
|
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.
|
Academic Article
|
The third international inflammatory breast cancer conference.
|
Academic Article
|
Response of an ERBB2-Mutated Inflammatory Breast Carcinoma to Human Epidermal Growth Factor Receptor 2-Targeted Therapy.
|
Academic Article
|
Erythropoiesis stimulating agents and clinical outcomes of invasive breast cancer patients receiving cytotoxic chemotherapy.
|
Academic Article
|
Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome.
|
Academic Article
|
Racial disparity in breast cancer survival: the impact of pre-treatment hematologic variables.
|
Academic Article
|
Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination.
|
Academic Article
|
TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients.
|
Academic Article
|
Relationship between Circulating Tumor Cells, Blood Coagulation, and Urokinase-Plasminogen-Activator System in Early Breast Cancer Patients.
|
Academic Article
|
Circulating tumor cells in newly diagnosed inflammatory breast cancer.
|
Academic Article
|
Molecular characterization and targeted therapeutic approaches in breast cancer.
|
Academic Article
|
Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy.
|
Academic Article
|
Blocking the adhesion cascade at the premetastatic niche for prevention of breast cancer metastasis.
|
Academic Article
|
Using circulating tumor cells to guide therapy in breast cancer: could this replace biopsies?
|
Academic Article
|
International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).
|
Academic Article
|
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
|
Academic Article
|
Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells.
|
Academic Article
|
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
|
Academic Article
|
The effects of erythropoiesis-stimulating agents on the short-term and long-term survivals in metastatic breast cancer patients receiving chemotherapy: a SEER population-based study.
|
Academic Article
|
Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups.
|
Academic Article
|
Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
|
Academic Article
|
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
|
Academic Article
|
A Preclinical Model of Inflammatory Breast Cancer to Study the Involvement of CXCR4 and ACKR3 in the Metastatic Process.
|
Academic Article
|
Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
|
Academic Article
|
Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner.
|
Academic Article
|
The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells.
|
Academic Article
|
Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer.
|
Academic Article
|
Breast Cancer Stem Cell Isolation.
|
Academic Article
|
MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer.
|
Academic Article
|
Mitosis in circulating tumor cells stratifies highly aggressive breast carcinomas.
|
Academic Article
|
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
|
Academic Article
|
Inflammatory breast cancer: a new approach.
|
Academic Article
|
Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors.
|
Academic Article
|
Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions.
|
Academic Article
|
Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
|
Academic Article
|
Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome.
|
Academic Article
|
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
|
Academic Article
|
GSK-3 inhibition overcomes chemoresistance in human breast cancer.
|
Academic Article
|
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
|
Academic Article
|
Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naĂŻve advanced breast cancer.
|
Academic Article
|
Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer.
|
Academic Article
|
Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer.
|
Academic Article
|
Developmental therapeutics for inflammatory breast cancer: Biology and translational directions.
|
Academic Article
|
Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients.
|
Academic Article
|
Phase Ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2 negative metastatic breast cancer (MBC).
|
Academic Article
|
Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development.
|
Academic Article
|
Metastatic breast cancer: focus on endocrine sensitivity.
|
Academic Article
|
Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
|
Academic Article
|
The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
|
Academic Article
|
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
|
Academic Article
|
Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.
|
Academic Article
|
Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer.
|
Academic Article
|
CCR5 governs DNA damage and breast cancer stem cell expansion.
|
Academic Article
|
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.
|
Academic Article
|
Emerging Innovative Therapeutic Approaches Leveraging Cyclin-Dependent Kinase Inhibitors to Treat Advanced Breast Cancer.
|
Academic Article
|
Comparing the Performances of Magnetic Resonance Imaging Size vs Pharmacokinetic Parameters to Predict Response to Neoadjuvant Chemotherapy and Survival in Patients With Breast Cancer.
|
Academic Article
|
Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference.
|
Academic Article
|
Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer.
|
Academic Article
|
Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.
|
Academic Article
|
Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy.
|
Academic Article
|
International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference.
|
Academic Article
|
Caloric restriction counteracts chemotherapy-induced inflammation and increases response to therapy in a triple negative breast cancer model.
|
Academic Article
|
Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer.
|
Academic Article
|
A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer.
|
Academic Article
|
Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer.
|
Academic Article
|
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications.
|
Academic Article
|
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
|
Academic Article
|
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
|
Academic Article
|
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.
|
Academic Article
|
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
|
Academic Article
|
Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancer.
|
Academic Article
|
Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer.
|
Academic Article
|
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?
|
Academic Article
|
Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA.
|
Academic Article
|
Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models.
|
Academic Article
|
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.
|
Academic Article
|
Palbociclib and Fulvestrant in Breast Cancer. Reply.
|
Academic Article
|
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.
|
Academic Article
|
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
|
Academic Article
|
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
|
Academic Article
|
Circulating Tumor Cells With Epithelial-to-mesenchymal Transition Phenotypes Associated With Inferior Outcomes in Primary Breast Cancer.
|
Academic Article
|
Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer.
|
Academic Article
|
Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium.
|
Academic Article
|
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
|
Academic Article
|
Emerging Role of Genomics and Cell-Free DNA in Breast Cancer.
|
Academic Article
|
Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology.
|
Academic Article
|
Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer.
|
Academic Article
|
Current state of clinical trials in breast cancer brain metastases.
|
Academic Article
|
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
|
Concept
|
Triple Negative Breast Neoplasms
|
Academic Article
|
Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer.
|
Academic Article
|
Time for a shift in molecular down staging in luminal breast cancer.
|
Academic Article
|
Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC).
|
Academic Article
|
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer.
|
Academic Article
|
Genetic Variants Detected Using Cell-Free DNA from Blood and Tumor Samples in Patients with Inflammatory Breast Cancer.
|
Academic Article
|
Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents.
|
Academic Article
|
Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.
|
Academic Article
|
Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors.
|
Academic Article
|
Overall survival of CDK4/6-inhibitors-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis.
|
Academic Article
|
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials.
|
Academic Article
|
Landscape of circulating tumour DNA in metastatic breast cancer.
|
Academic Article
|
Minimal Residual Disease in Patients With Nonmetastatic Triple-Negative Breast Cancer: Positive, Negative, or a More Complex Issue?
|
Academic Article
|
Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools.
|
Academic Article
|
Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
|
Academic Article
|
The use of serial circulating tumor DNA (ctDNA) to detect resistance alterations in progressive metastatic breast cancer.
|
Academic Article
|
Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
|
Academic Article
|
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5?Years of Follow-Up.
|
Academic Article
|
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.
|
Academic Article
|
New Treatment Strategies for the Inflammatory Breast Cancer.
|
Academic Article
|
Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer.
|
Academic Article
|
Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer.
|
Academic Article
|
Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer.
|
Academic Article
|
ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer.
|
Academic Article
|
Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancer.
|
Academic Article
|
Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer.
|
Academic Article
|
Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China.
|
Academic Article
|
Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC).
|
Academic Article
|
EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer.
|
Academic Article
|
Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3.
|
Academic Article
|
Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer.
|
Academic Article
|
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC.
|
Academic Article
|
Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis.
|
Academic Article
|
Standard of Care in Hormone Receptor-Positive Metastatic Breast Cancer: Can We Improve the Current Regimens or Develop Better Selection Tools?
|
Academic Article
|
Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast Cancer.
|
Academic Article
|
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation.
|
Academic Article
|
CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome.
|
Academic Article
|
Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism.
|
Academic Article
|
Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience.
|
Academic Article
|
Beta 2-Adrenergic Receptor in Circulating Cancer-Associated Cells Predicts for Increases in Stromal Macrophages in Circulation and Patient Survival in Metastatic Breast Cancer.
|
Academic Article
|
MARCKS as a Potential Therapeutic Target in Inflammatory Breast Cancer.
|
Academic Article
|
A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix? PC1 System.
|
Academic Article
|
Machine learning-assisted elucidation of CD81-CD44 interactions in promoting cancer stemness and extracellular vesicle integrity.
|
Academic Article
|
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer.
|
Academic Article
|
Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer.
|
Academic Article
|
Proteolytic regulation of CD73 by TRIM21 orchestrates tumor immunogenicity.
|
Academic Article
|
Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide.
|
Academic Article
|
A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases.
|
Academic Article
|
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment.
|
Academic Article
|
Computational ranking-assisted identification of Plexin-B2 in homotypic and heterotypic clustering of circulating tumor cells in breast cancer metastasis.
|
Academic Article
|
Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date.
|
Academic Article
|
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer.
|
Academic Article
|
Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis.
|
Academic Article
|
Circulating Tumor DNA and Unique Actionable Genomic Alterations in the Longitudinal Monitoring of Metastatic Breast Cancer: A Case of FGFR2-KIAA1598 Gene Fusion.
|
Academic Article
|
Dynamic glycoprotein hyposialylation promotes chemotherapy evasion and metastatic seeding of quiescent circulating tumor cell clusters in breast cancer.
|
Academic Article
|
Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer.
|
Academic Article
|
ICAM-1-suPAR-CD11b Axis Is a Novel Therapeutic Target for Metastatic Triple-Negative Breast Cancer.
|
Academic Article
|
The immunogram of inflammatory breast cancer.
|
Academic Article
|
Latest advances in clinical studies of circulating tumor cells in early and metastatic breast cancer.
|
Academic Article
|
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis.
|
Academic Article
|
Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 Trial.
|
Academic Article
|
Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort.
|
Academic Article
|
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
|
Academic Article
|
Circulating tumor cells et al.: towards a comprehensive liquid biopsy approach in breast cancer.
|
Academic Article
|
Inflammatory breast cancer: Epidemiologic data and therapeutic results.
|
Academic Article
|
Modeling the management of patients with human epidermal growth factor receptor 2-positive breast cancer with liquid biopsy: the future of precision medicine.
|
Academic Article
|
Low-pass whole genome sequencing of circulating tumor cells to evaluate chromosomal instability in triple-negative breast cancer.
|
Academic Article
|
[18F]-Fluoroestradiol (FES) brain PET in the evaluation of patients with estrogen receptor positive breast cancer and known or suspected brain metastases.
|
Academic Article
|
Prognostic and therapeutic implications of tumor-restrictive type III collagen in the breast cancer microenvironment.
|
Academic Article
|
Tuning Immune-Cold Tumor by Suppressing USP10/B7-H4 Proteolytic Axis Reinvigorates Therapeutic Efficacy of ADCs.
|
Academic Article
|
Adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: one fits all?
|
Academic Article
|
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study.
|
Academic Article
|
Integrating Machine Learning-Predicted Circulating Tumor Cells (CTCs) and circulating tumor DNA (ctDNA) in Metastatic Breast Cancer: a proof of principle study on endocrine resistance profiling.
|